Nsclc 2nd line

950 views
817 views

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
950
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
42
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Nsclc 2nd line

  1. 1. Second Line Treatment of metastatic Non-Small Cell Lung Cancer Update from the World Conference on Lung Cancer G. Nsouli MDTuesday, August 9, 2011
  2. 2. Tuesday, August 9, 2011
  3. 3. Tuesday, August 9, 2011
  4. 4. Tuesday, August 9, 2011
  5. 5. Weekly vs 3-weekly Docetaxel Overall survival (OAS) curves by treatment arm. Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second- Line Treatment of Advanced Non– Small-Cell Lung Cancer Di MaioTuesday, August 9, 2011 J.Clin. Oncol.
  6. 6. Weekly vs 3-weekly Docetaxel Treatment effect on survival within major patient subgroups. PS, performance status. Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second- Line Treatment of Advanced Non– Small-Cell Lung Cancer Di MaioTuesday, August 9, 2011 J.Clin. Oncol.
  7. 7. Pemetrexed vs. Docetaxel in second line Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non– Small-Cell Lung CancerPreviously Treated With ChemotherapyJ. Clin. Oncol 2004; 22:1589-97Tuesday, August 9, 2011
  8. 8. Survival and Toxicity Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non– Small-Cell Lung CancerPreviously Treated With ChemotherapyJ. Clin. Oncol 2004; 22:1589-97Tuesday, August 9, 2011
  9. 9. Median time to progression (A) for patients younger than 70 years of age: pemetrexed, 3.0 months v docetaxel, 3.9 months (hazard ratio [HR], 1.03; ; (B) for patients 70 years of age: pemetre-xed, 4.6 months v docetaxel, 2.9 months (HR,Benefit0.72; Elderly Patients From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized PhaseIII Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non– Small-Cell Lung Cancer Weiss G J.Clin. Oncol. 006;24:4405-11Tuesday, August 9, 2011
  10. 10. Median overall survival time (A) for patients younger than 70 years of age: pemetrexed, 7.8 months v docetaxel, 8.0 months HR], 1.02; (B) for patients 70 years of age: pemetrexed, 9.5 months v docetaxel, 7.7 months (HR, 0.86; Patients Benefit Elderly From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized PhaseIII Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non– Small-Cell Lung Cancer Weiss G J.Clin. Oncol. 006;24:4405-11Tuesday, August 9, 2011
  11. 11. Current Guidelines in Second line treatment of NSCLC • For patients with disseminated metastatic disease, both second-line cytotoxic chemotherapy and small molecule epidermal growth factor receptor (EGFR) inhibitors may provide palliation and increase survival. • When symptoms are due to progressive disease within the chest or from metastatic involvement of a single or limited number of sites, radiation therapy (RT) is often useful for palliation.Tuesday, August 9, 2011
  12. 12. Tuesday, August 9, 2011
  13. 13. Tuesday, August 9, 2011
  14. 14. Tuesday, August 9, 2011
  15. 15. Tuesday, August 9, 2011
  16. 16. Tuesday, August 9, 2011
  17. 17. Tuesday, August 9, 2011
  18. 18. Tuesday, August 9, 2011
  19. 19. Tuesday, August 9, 2011
  20. 20. Tuesday, August 9, 2011
  21. 21. Tuesday, August 9, 2011
  22. 22. Tuesday, August 9, 2011
  23. 23. Tuesday, August 9, 2011
  24. 24. Tuesday, August 9, 2011
  25. 25. Tuesday, August 9, 2011
  26. 26. Tuesday, August 9, 2011
  27. 27. Tuesday, August 9, 2011
  28. 28. Tuesday, August 9, 2011
  29. 29. Tuesday, August 9, 2011
  30. 30. Tuesday, August 9, 2011
  31. 31. Tuesday, August 9, 2011
  32. 32. Tuesday, August 9, 2011
  33. 33. Tuesday, August 9, 2011
  34. 34. Tuesday, August 9, 2011
  35. 35. Tuesday, August 9, 2011
  36. 36. Tuesday, August 9, 2011
  37. 37. Tuesday, August 9, 2011
  38. 38. Tuesday, August 9, 2011
  39. 39. Tuesday, August 9, 2011
  40. 40. Tuesday, August 9, 2011
  41. 41. Tuesday, August 9, 2011
  42. 42. Tuesday, August 9, 2011
  43. 43. Tuesday, August 9, 2011

×